NEW YORK, Dec. 18 (Genome Web News) - Calgary Laboratory Services and Tm Bioscience plan to co-develop a gene-based diagnostic to help physicians identify and characterize nosocomial drug-resistant Staphylococcus aureus.
Currently, most labs employ cultures to diagnose the pathogen, methicillin-resistant S. aureus. And though molecular tests are used routinely at CLS and other large labs, "there are no standard commercial molecular assays available" to detect and characterize the pathogen.
The partnership marks the first time Tm Bioscience, based in Toronto, will focus on an infectious disease, the company said. CLS is located in Calgary and operates 18 patient-service centers and four hospital-based acute-care sites in the region, a CLS spokeswoman said.